Twist Bioscience (TWST) EBT (2017 - 2026)

Twist Bioscience has disclosed EBT across 10 years of filings, most recently posting -$44.0 million for Q1 2026.

• In Q1 2026, EBT fell 12.32% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at -$80.5 million (up 57.79% YoY), while the FY2025 annual figure was -$77.0 million, up 63.03% from the prior year.
• EBT declined to -$44.0 million in Q1 2026, from -$30.3 million in the prior quarter.
• Over the last five years, EBT for TWST reached as high as $20.6 million in Q2 2025 and fell as low as -$85.4 million in Q2 2024.
• The 5-year median for EBT is -$44.0 million (2026), against an average of -$43.2 million.
• Annual changes were most pronounced in 2022 — EBT tumbled 60.65% — and 2025, when it soared 124.11%.
• A 5-year view of EBT shows it stood at -$41.7 million in 2022, then slipped by 2.73% to -$42.9 million in 2023, then rose by 26.56% to -$31.5 million in 2024, then gained by 3.95% to -$30.3 million in 2025, then sank by 45.36% to -$44.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$44.0 million, -$30.3 million, and -$26.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.